Skip to main content
English
中文
Log In
Log in
Log in with ORCID
NTU Single Sign On
Have you forgotten your password?
Home
.National Taiwan University / 國立臺灣大學
Project / 研究計畫
The Impact of Lung Microbiome in the Pathogenesis and the Progression of Fibrosing Interstitial Lung Disease = 肺微生物叢基因體對纖維化間質性肺病病理機轉和疾病進展的影響
The Impact of Lung Microbiome in the Pathogenesis and the Progression of Fibrosing Interstitial Lung Disease = 肺微生物叢基因體對纖維化間質性肺病病理機轉和疾病進展的影響
Details
Primary Data
Project title
肺微生物叢基因體對纖維化間質性肺病病理機轉和疾病進展的影響
Internal ID
MOST110-2314-B002-259
Principal Investigator
YEN-FU CHEN
Start Date
August 1, 2021
End Date
July 31, 2022
Investigators
HAO-CHIEN WANG
PING-HUNG KUO
NING CHIEN
CHONG-JEN YU
HSIN-HAN HOU
KAI-LUN YU
JUNG-YIEN CHIEN
CHUNG-MING CHEN
Organizations
Internal Medicine-NTUHYL
Partner Organizations
National Science and Technology Council
Description
Keywords
Fibrosing Interstitial lung diseases (ILDs)
Idiopathic pulmonary fibrosis (IPF)
lung microbiome
pulmonary metabolites
16S ribosomal RNA gene sequencing
Quantification of high resolution computed tomography (HRCT)
Description
纖維化間質性肺病(Fibrosing ILD)目前仍沒有很好的生物標記來預測患者的疾病進展及惡化,本研究將探討肺微生物叢基因體功能失調(lung microbiome dysbiosis)對肺部免疫的影響及其在間質性肺病纖維化的致病機轉, 調節肺微生物菌群也許將來可以提供治療纖維化間質性肺病的新方向。未來我們也將運用16S核醣體核糖核酸定序來鑑定與纖維化進展相關的肺微生物組的特定分類群,並進一步使用肺微生物叢基因體、定量高解析度電腦斷層掃描結合各種生物標記和臨床資訊,來開發纖維化間質性肺病未來風險的預測模型。我們研究的發現可能為將來的纖維化間質性肺病提供與微生物組相關的新穎治療策略。
Show more